RxDoctor Payments Data

Paolo Tarantino

Medical Oncology · Boston, MANPI 1619747359

Payments from drug & device makers

$428,765in general payments, 2019–2025

Across 142 payments — averaging $3019.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$368K
  • Astrazeneca UK Limited$41K
  • Gilead$9K
  • F. Hoffmann-la Roche AG$3K
  • Stemline Therapeutics Inc.$2K
  • Sanofi$2K
  • plus $3K from 3 others
$11,938in research payments, 2019–2025

Across 3 payments — averaging $3979.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$12K

What the payments were for

  • Consulting fees$70,72681%
  • Speaking & faculty fees$1,8622%
  • Travel & lodging$8,2389%
  • Food & beverage$6,0887%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca61$368,350
Astrazeneca UK Limited36$40,909
Gilead20$8,816
F. Hoffmann-la Roche AG3$3,280
Stemline Therapeutics Inc.6$2,473
Sanofi5$2,251
Daiichi Sankyo Inc.6$2,214
Pfizer2$248
Novartis3$224

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$428,765 in reported general payments places this provider in the 65th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →